Challenge:

A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment with a very short deadline.

Solution:

Alacrita's cancer immunotherapy expert conducted the analysis within four days, which included a review of a comprehensive data room encompassing preclinical, clinical, regulatory, manufacturing and IP matters. Our report identified the areas of key risk in the project and suggested how to mitigate them. The target company reviewed our report and agreed with the findings including the major areas of risk that we identified.